| STUDY |
In "Biotech 2002," his most recent industry report, investment banker G. Steven Burrill notes that while the technology platform business model first appeared to make sense with its focus on delivering products to speed drug discovery, it soon became clear that most new technologies address only a portion of the drug discovery continuum. "As essential as genomics and its ancillary technologies are to the life sciences, few of these firms were able to convince investors of their ability to generate and sustain profits using their existing business models," Burrill writes. So instead of offering tools and services, genomics firms believe they can create long-term business value by transitioning into drug R&D, a business model proven by existing biopharmaceutical producers. Most genomics firms have begun the difficult transformation through a variety of changes. These can include new managers with drug-industry experience; in-licensing of product candidates; acquisitions to gain technology and infrastructure, including drug R&D, clinical capabilities, and manufacturing; partnerships and alliances; and a decreased emphasis on sequencing services and database sales |
| UPDATE | 10.02 |
| LITERATURE REF. | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |